Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'. Br J Cancer.

Imafuku, Keisuke, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, and Hiroo Hata. "Comment On ‘Efficacy and Toxicity of Treatment With the Anti-CTLA-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-PD-1 Therapy'." Br J Cancer 2017.

Imafuku, Keisuke, et al. "Comment On ‘Efficacy and Toxicity of Treatment With the Anti-CTLA-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-PD-1 Therapy'." Br J Cancer 2017.